BioCatalystWatch
NCELWorkspace / NCEL / OverviewCompany library
Price
Market cap
Next catalystPlanned Phase 1/2a commencement in Q2 2027, subject to applicable regulatory requirements; November guidance restates 2027NCEL-101 with tegoprubart — planned Phase 1/2a · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

NCEL-101NCEL-101 with tegoprubart — planned Phase 1/2a

Cell therapy

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

AEX-2

OX1R × OX2R

Upcoming / outlook

AEX-41

OX1R × OX2R × CTSH × Sigma-1 receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

AEX-41

OX1R × OX2R × CTSH × Sigma-1 receptor

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AEX-41

OX1R × OX2R × CTSH × Sigma-1 receptor

Upcoming / outlook

AEX-41

OX1R × OX2R × CTSH × Sigma-1 receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

AEX-2

OX1R × OX2R

Upcoming / outlook

NCEL-101NCEL-101 with tegoprubart — planned Phase 1/2a

Cell therapy

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

AstroRx®

Cell therapy

PreINDP1P2P3FilingApproved
AstroRx®

Cell therapy

AstroRx®

Cell therapy

Approved / commercial

History / paused

Dopamine transporter × Norepinephrine transporter × 5-HT1A × Mu-opioid receptor × OX2R × Kappa-opioid receptor × Delta-opioid receptor

Dopamine transporter × Norepinephrine transporter × 5-HT1A × Mu-opioid receptor × OX2R × Kappa-opioid receptor × Delta-opioid receptor

PreINDP1P2P3FilingApproved

Dopamine transporter × Norepinephrine transporter × 5-HT1A × Mu-opioid receptor × OX2R × Kappa-opioid receptor × Delta-opioid receptor

Dopamine transporter × Norepinephrine transporter × 5-HT1A × Mu-opioid receptor × OX2R × Kappa-opioid receptor × Delta-opioid receptor

PreINDP1P2P3FilingApproved

Dopamine transporter × Norepinephrine transporter × 5-HT1A × Mu-opioid receptor × OX2R × Kappa-opioid receptor × Delta-opioid receptor

PreINDP1P2P3FilingApproved

Orexin-2 receptor

Approved

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Market Reaction / Supply Context

Market Structure

NCEL PR & News

NCEL SEC archive